192 related articles for article (PubMed ID: 29385581)
1. Genetic test reporting of CDKN2A provides informational and motivational benefits for managing melanoma risk.
Aspinwall LG; Stump TK; Taber JM; Drummond DM; Kohlmann W; Champine M; Leachman SA
Transl Behav Med; 2018 Jan; 8(1):29-43. PubMed ID: 29385581
[TBL] [Abstract][Full Text] [Related]
2. Priority of Risk (But Not Perceived Magnitude of Risk) Predicts Improved Sun-Protection Behavior Following Genetic Counseling for Familial Melanoma.
Taber JM; Aspinwall LG; Drummond DM; Stump TK; Kohlmann W; Champine M; Cassidy P; Leachman SA
Ann Behav Med; 2021 Feb; 55(1):24-40. PubMed ID: 32415830
[TBL] [Abstract][Full Text] [Related]
3. Genetic Test Reporting and Counseling for Melanoma Risk in Minors May Improve Sun Protection Without Inducing Distress.
Stump TK; Aspinwall LG; Kohlmann W; Champine M; Hauglid J; Wu YP; Scott E; Cassidy P; Leachman SA
J Genet Couns; 2018 Aug; 27(4):955-967. PubMed ID: 29349527
[TBL] [Abstract][Full Text] [Related]
4. Genetic test reporting enhances understanding of risk information and acceptance of prevention recommendations compared to family history-based counseling alone.
Taber JM; Aspinwall LG; Stump TK; Kohlmann W; Champine M; Leachman SA
J Behav Med; 2015 Oct; 38(5):740-53. PubMed ID: 26178773
[TBL] [Abstract][Full Text] [Related]
5. CDKN2A testing and genetic counseling promote reductions in objectively measured sun exposure one year later.
Stump TK; Aspinwall LG; Drummond DM; Taber JM; Kohlmann W; Champine M; Cassidy PB; Petrie T; Liley B; Leachman SA
Genet Med; 2020 Jan; 22(1):26-34. PubMed ID: 31371819
[TBL] [Abstract][Full Text] [Related]
6. Genetic testing for hereditary melanoma and pancreatic cancer: a longitudinal study of psychological outcome.
Aspinwall LG; Taber JM; Leaf SL; Kohlmann W; Leachman SA
Psychooncology; 2013 Feb; 22(2):276-89. PubMed ID: 23382133
[TBL] [Abstract][Full Text] [Related]
7. CDKN2A/p16 genetic test reporting improves early detection intentions and practices in high-risk melanoma families.
Aspinwall LG; Leaf SL; Dola ER; Kohlmann W; Leachman SA
Cancer Epidemiol Biomarkers Prev; 2008 Jun; 17(6):1510-9. PubMed ID: 18559569
[TBL] [Abstract][Full Text] [Related]
8. Melanoma genetic testing, counseling, and adherence to skin cancer prevention and detection behaviors.
Glanz K; Volpicelli K; Kanetsky PA; Ming ME; Schuchter LM; Jepson C; Domchek SM; Armstrong K
Cancer Epidemiol Biomarkers Prev; 2013 Apr; 22(4):607-14. PubMed ID: 23392000
[TBL] [Abstract][Full Text] [Related]
9. Unaffected family members report improvements in daily routine sun protection 2 years following melanoma genetic testing.
Aspinwall LG; Taber JM; Kohlmann W; Leaf SL; Leachman SA
Genet Med; 2014 Nov; 16(11):846-53. PubMed ID: 24763292
[TBL] [Abstract][Full Text] [Related]
10. Impact of melanoma genetic test reporting on perceived control over melanoma prevention.
Aspinwall LG; Stump TK; Taber JM; Kohlmann W; Leaf SL; Leachman SA
J Behav Med; 2015 Oct; 38(5):754-65. PubMed ID: 25822116
[TBL] [Abstract][Full Text] [Related]
11. Uptake of genetic counseling, genetic testing and surveillance in hereditary malignant melanoma (CDKN2A) in Norway.
Levin T; Mæhle L
Fam Cancer; 2017 Apr; 16(2):257-265. PubMed ID: 27804060
[TBL] [Abstract][Full Text] [Related]
12. Phenocopies in melanoma-prone families with germ-line CDKN2A mutations.
Helgadottir H; Olsson H; Tucker MA; Yang XR; Höiom V; Goldstein AM
Genet Med; 2018 Sep; 20(9):1087-1090. PubMed ID: 29215650
[TBL] [Abstract][Full Text] [Related]
13. Interactive Beliefs about Genes and Behavior Predict Improved Sun Protection Following Melanoma Genetic Counseling.
Aspinwall LG; Drummond DM; Stump TK; Kohlmann WK; Leachman SA
Ann Behav Med; 2022 Aug; 56(8):816-829. PubMed ID: 35179177
[TBL] [Abstract][Full Text] [Related]
14. Pediatric melanoma in melanoma-prone families.
Goldstein AM; Stidd KC; Yang XR; Fraser MC; Tucker MA
Cancer; 2018 Sep; 124(18):3715-3723. PubMed ID: 30207590
[TBL] [Abstract][Full Text] [Related]
15. Genetic counselling and high-penetrance susceptibility gene analysis reveal the novel CDKN2A p.D84V (c.251A>T) mutation in melanoma-prone families from Italy.
Borroni RG; Manganoni AM; Grassi S; Grasso M; Diegoli M; Giorgianni C; Favalli V; Pavoni L; Cespa M; Arbustini E
Melanoma Res; 2017 Apr; 27(2):97-103. PubMed ID: 28060055
[TBL] [Abstract][Full Text] [Related]
16. Parental preferences for CDKN2A/p16 testing of minors.
Taber JM; Aspinwall LG; Kohlmann W; Dow R; Leachman SA
Genet Med; 2010 Dec; 12(12):823-38. PubMed ID: 21045708
[TBL] [Abstract][Full Text] [Related]
17. Hereditary melanoma and predictive genetic testing: why not?
Riedijk SR; de Snoo FA; van Dijk S; Bergman W; van Haeringen A; Silberg S; van Elderen TM; Tibben A
Psychooncology; 2005 Sep; 14(9):738-45. PubMed ID: 15744786
[TBL] [Abstract][Full Text] [Related]
18. Increased prevalence of lung, breast, and pancreatic cancers in addition to melanoma risk in families bearing the cyclin-dependent kinase inhibitor 2A mutation: implications for genetic counseling.
Potrony M; Puig-Butillé JA; Aguilera P; Badenas C; Carrera C; Malvehy J; Puig S
J Am Acad Dermatol; 2014 Nov; 71(5):888-95. PubMed ID: 25064638
[TBL] [Abstract][Full Text] [Related]
19. Pancreatic cancer and melanoma related perceptions and behaviors following disclosure of CDKN2A variant status as a research result.
Leof ER; Zhu X; Rabe KG; McCormick JB; Petersen GM; Radecki Breitkopf C
Genet Med; 2019 Nov; 21(11):2468-2477. PubMed ID: 30992552
[TBL] [Abstract][Full Text] [Related]
20. Perceptions of genetic research and testing among members of families with an increased risk of malignant melanoma.
Bränström R; Kasparian NA; Affleck P; Tibben A; Chang YM; Azizi E; Baron-Epel O; Bergman W; Chan M; Davies J; Ingvar C; Kanetsky PA; van Leeuwen E; Olsson H; Gruis NA; Brandberg Y; Newton-Bishop J
Eur J Cancer; 2012 Nov; 48(16):3052-62. PubMed ID: 22726816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
